Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 5, 2011, Pages 1016-1023

  Binkhorst, Lisette ^a   Mathijssen, Ron H J ^a   Ghobadi Moghaddam Helmantel, Inge M ^a   de Bruijn, Peter ^a   van Gelder, Teun ^a   Wiemer, Erik A C ^a   Loos, Walter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

4 Hydroxy tamoxifen; Endoxifen; LC MS MS; N desmethyl tamoxifen; Tamoxifen

Indexed keywords

4 HYDROXY TAMOXIFEN; ACETONE; ACETONITRILE; AMMONIUM FORMATE; DRUG METABOLITE; ENDOXIFEN; FORMIC ACID; N DESMETHYL TAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; ELECTROSPRAY; HUMAN; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CALIBRATION; CHROMATOGRAPHY, LIQUID; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAMOXIFEN;

EID: 80052791490     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.08.002     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467.
2. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. Colleoni M., Gelber S., Goldhirsch A., Aebi S., Castiglione-Gertsch M., Price K.N., Coates A.S., Gelber R.D. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer. J. Clin. Oncol. 2006, 24:1332-1341. International Breast Cancer Study Group Trial 13-93.
4. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 2005, 97:1652-1662.
5. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., Ingle J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005, 23:9312-9318.
6. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., Simon W., Eichelbaum M., Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 2007, 25:5187-5193.
7. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95:1758-1764.
8. Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 1997, 53:171-178.
9. Desta Z., Ward B.A., Soukhova N.V., Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 2004, 310:1062-1075.
10. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., Skaar T.C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85:151-159.
11. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 2005, 55:471-478.
12. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R.M., Rae J.M., Hayes D.F., Flockhart D.A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 2005, 97:30-39.
13. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., Flockhart D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 2006, 80:61-74.
14. Murdter T.E., Schroth W., Bacchus-Gerybadze L., Winter S., Heinkele G., Simon W., Fasching P.A., Fehm T., Eichelbaum M., Schwab M., Brauch H. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clin. Pharmacol. Ther. 2011, 89:708-717.
15. Teunissen S.F., Rosing H., Schinkel A.H., Schellens J.H., Beijnen J.H. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. Anal. Chim. Acta 2010, 683:21-37.
16. Teunissen S.F., Rosing H., Koornstra R.H., Linn S.C., Schellens J.H., Schinkel A.H., Beijnen J.H. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:2519-2529.
17. Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4′-hydroxylated metabolites in breast cancer patients. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2010, 878:3402-3414.
18. Teunissen S.F., Jager N.G., Rosing H., Schinkel A.H., Schellens J.H., Beijnen J.H. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2011, 879:1677-1685.
19. A.J. de Graan, S.F. Teunissen, F.Y.F.L. de Vos, W.J. Loos, R.H. van Schaik, F.E. de Jongh, A.I. de Vos, R.J. van Alphen, B. van der Holt, J. Verweij, C. Seynaeve, J.H. Beijnen, R.H. Mathijssen, Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment, J. Clin. Oncol. 29 (2011 Jul 18) [Epub ahead of print] doi:10.1200/JCO.2010.31.4427.
20. Rosing H., Man W.Y., Doyle E., Bult A., Beijnen J.H. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. J. Liq. Chromatogr. Relat. Technol. 2000, 23:329-354.
21. de Bruijn P., Moghaddam-Helmantel I.M., de Jonge M.J., Meyer T., Lam M.H., Verweij J., Wiemer E.A., Loos W.J. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50:977-982.
22. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
23. Wille S.M., Lambert W.E. Recent developments in extraction procedures relevant to analytical toxicology. Anal. Bioanal. Chem. 2007, 388:1381-1391.